Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

Chronic Hepatitis B Clinical Trial

Official title:

A Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06431438
• Other study ID #: TQA3810-I-01
• Status: Completed
• Phase: Phase 1
• Start date: October 1, 2021
• Est. completion date: November 20, 2023

Study information

• Verified date: May 2024
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was a single-center study, including randomized, double-blind, placebo-controlled, single-dose escalation study, multiple-dose study, food effect on pharmacokinetics and drug metabolism transformation study, drug interaction study. To evaluate the tolerability, pharmacokinetics and metabolic transformation of TQA3810 in healthy subjects after single or multiple doses of TQA3810, the drug-drug interactions between TQA3810 tablets and entecavir dispersible tablets, and the pharmacokinetic properties of TQA3810 tablets in combination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 759
• Est. completion date: November 20, 2023
• Est. primary completion date: November 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;

• Able to complete the study according to the requirements of the trial protocol;

• The participants (including their partners) are willing to voluntarily use effective contraceptive methods within 6 months from screening until the last dose of study drug, as detailed in the Appendix;

• Male and female subjects aged 18-55 years old (including 18 and 55 years old);

• The body weight of male subjects should not be less than 50 kg and the body weight of female subjects should not be less than 45 kg. Body mass index (BMI) = weight (kg)/height 2 (m2), BMI in the range of 18-28 kg/m2 (including the cut-off value);

• The physical examination and vital signs were normal or abnormal without clinical significance.

Exclusion Criteria:

• Smoking more than 5 cigarettes per day in the 3 months before the study;

• Allergic constitution (multi-drug and food allergy);

• A history of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 ml wine);

• Donation or massive blood loss (> 400 mL) within 3 months before screening;

• Taking any drugs that alter liver enzyme activity 28 days before screening;

• Have taken any prescription medication, over-the-counter medication, any vitamin product or herbal medicine within 14 days before screening;

• Those who had taken special diet (including dragon fruit, mango, grapefruit, etc.) or had strenuous exercise within 2 weeks before screening, or had other factors affecting drug absorption, distribution, metabolism, and excretion;

• Combined with the following inhibitors or inducers of CYP3A4, P-gp, or Bcrp, such as itraconazole, ketoconazole, or dronedarone, within three months before taking the study drug;

• A recent major change in diet or exercise habits;

• Have taken a study drug or participated in a clinical trial of the drug within three months before taking the study drug;

• A history of dysphagia or any gastrointestinal disorder affecting drug absorption or a history of cholecystectomy or biliary tract disease;

• Have any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers;

• With severe systemic diseases and related medical history (including subjects with active or occult tuberculosis, a history of tuberculosis, or clinical manifestations suspected of tuberculosis), as well as immune system diseases and medical history;

• Had systemic or local infection within 2 months prior to screening, and were hospitalized for severe infection and/or required intravenous antibiotics;

• Subjects who were unable to tolerate a standard meal;

• An electrocardiogram (ECG) abnormalities have clinical significance;

• The female subjects were lactating or seropositive for pregnancy during the screening or test period;

• Clinically significant abnormalities on clinical examination or other clinical findings within 6 months prior to screening (including but not limited to gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, oncologic, pulmonary, immune, psychiatric, or cardio-cerebrovascular diseases);

• Clinically significant fundus lesions (symptomatic cotton-like fundus changes) and retinopathy;

• Viral hepatitis (including hepatitis B and C), AIDS antibody, treponema pallidum antibody positive;

• From the screening stage to the onset of acute illness or concomitant medication before study medication;

• Consumption of chocolate, any caffeinated or xanthine-rich food or beverage 24 hours before taking the study drug;

• Have taken any alcohol-based product within 24 hours before taking the study medication;

• Having a positive urine drug screen or having a history of drug abuse or drug use in the past 5 years;

• Subjects with other factors considered by the investigator to be ineligible for the trial.

Related Conditions & MeSH terms

• Chronic Hepatitis B
• Hepatitis B
• Hepatitis B, Chronic

Intervention

Drug:
• TQA3810
TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Locations

Country	Name	City	State
China	Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events	Occurrence of all adverse events (AEs), serious adverse events (SAEs), and treatment-related adverse events (TEAEs) were recorded.	From the subject signed the informed consent form to 30 days after the last dose
Secondary	Cmax	Maximum plasma drug concentration	Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose
Secondary	Tmax	To maximum plasma drug concentration time.	Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose
Secondary	Half-life (t1/2)	Drug half-life in plasma.	Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose
Secondary	AUC0-t	Plasma drug concentration from time 0 to the last measurable area under the drug concentration time curve.	Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose
Secondary	AUC0-8	Area under the plasma drug concentration time curve from time 0 to infinity.	Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose